亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

医学 中止 埃尔特罗姆博帕格 抗血栓 内科学 外科 血栓形成 血小板 入射(几何) 危险系数 胃肠病学 免疫性血小板减少症 置信区间 光学 物理
作者
Francesca Palandri,Elena Rossi,Daniela Bartoletti,Antonietta Ferretti,Marco Ruggeri,Elisa Lucchini,Valentina Carrai,Wilma Barcellini,Andrea Patriarca,Elena Rivolti,Ugo Consoli,Silvia Cantoni,Esther Natalie Olíva,Federico Chiurazzi,Giovanni Caocci,Gaetano Giuffrida,Alessandra Borchiellini,Giuseppe Auteri,Erminia Baldacci,Giuseppe Carli,Daniela Nicolosi,Emanuele Sutto,Monica Carpenedo,Michèle Cavo,Maria Gabriella Mazzucconi,Francesco Zaja,Valerio De Stefano,Francesco Rodeghiero,Nicola Vianelli
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (7): 571-583 被引量:36
标识
DOI:10.1182/blood.2021010735
摘要

Abstract The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary immune thrombocytopenia (ITP) are unknown. We investigated TRA response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROTs) in 384 patients with ITP aged ≥60 years. After 3 months, 82.5% and 74.3% of eltrombopag- and romiplostim-treated patients, respectively, achieved a response; 66.7% maintained the response (median follow-up, 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; although no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. Thirty-four major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, while on TRAs and were associated with thrombosis history (subdistribution hazard ratio, 2.04, P = .05) and platelet count <20 × 109/L (subdistribution hazard ratio, 1.69; P = .04), respectively, at TRA start. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but 1 during persisting TRA treatment (incidence rate, 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRAs; 53 (13.8%) patients maintained SROTs, which were associated with TRA discontinuation in complete response (P < .001). Very old age (≥75 years; 41.1%) was associated with the more frequent start of TRAs in the persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in older patients with ITP, with no fatal hemorrhages and with SROTs in a significant portion of patients. Caution is warranted in patients with a history of thrombosis, and a careful risk/benefit balance should be considered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
粽子发布了新的文献求助10
3秒前
顺利山柏完成签到 ,获得积分10
11秒前
无花果应助lixiaojin采纳,获得10
27秒前
zpli完成签到 ,获得积分10
29秒前
Nefelibata完成签到,获得积分10
32秒前
35秒前
lixiaojin发布了新的文献求助10
40秒前
俭朴夜雪完成签到,获得积分10
41秒前
Limerencia完成签到,获得积分10
47秒前
lixiaojin完成签到,获得积分10
51秒前
打打应助wyg1994采纳,获得10
52秒前
烟花应助基围虾采纳,获得10
52秒前
下午好完成签到 ,获得积分10
53秒前
gc完成签到 ,获得积分10
55秒前
1分钟前
1分钟前
八月发布了新的文献求助30
1分钟前
今后应助科研通管家采纳,获得10
1分钟前
丘比特应助科研通管家采纳,获得10
1分钟前
1分钟前
基围虾发布了新的文献求助10
2分钟前
吴嘉俊完成签到 ,获得积分10
2分钟前
largpark完成签到 ,获得积分10
2分钟前
樊冀鑫发布了新的文献求助20
2分钟前
上官若男应助zyc采纳,获得10
2分钟前
uikymh完成签到 ,获得积分0
2分钟前
派大星完成签到,获得积分10
2分钟前
2分钟前
2分钟前
zyc发布了新的文献求助10
2分钟前
hhhhhhh完成签到,获得积分10
2分钟前
2分钟前
燕海雪发布了新的文献求助10
2分钟前
zyc完成签到,获得积分10
2分钟前
潮人完成签到 ,获得积分10
3分钟前
燕海雪完成签到,获得积分10
3分钟前
3分钟前
Ni发布了新的文献求助10
3分钟前
3分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784062
捐赠科研通 2444016
什么是DOI,文献DOI怎么找? 1299609
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600989